Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4840-4848

  Fricke, Ingo ^a   Mirza, Noweeda ^a   Dupont, Jakob ^b   Lockhart, Craig ^c   Jackson, Autumn ^c   Lee, Ji Hyun ^a   Sosman, Jeffrey A ^c   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HYBRID PROTEIN; MITOGENIC AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN TRAP PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BLADDER CANCER; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LUNG SMALL CELL CANCER; MALE; MONONUCLEAR CELL; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RECTUM CARCINOMA; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SUPPRESSOR CELL; THYMOMA; THYROID CANCER;

ADULT; AGED; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548125294     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0409     Document Type: Article

References (38)

1. Gabrilovich D. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003;5:140-6.
4. Toi M. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996;77:1101-6.
5. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur JCancer 1996;32A:2451-60.
6. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
7. Gabrilovich D. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
8. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA Carbone DP. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-20.
9. Ohm JE. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260-8.
10. Ishida T, Chada S, Stipanov M, et al. Dendritic cells transduced with wild type p53 gene elicit potent antitumor immune responses. Clin Exp Immunol 1999;117:244-51.
11. Ishida T, Oyama T, Carbone D, Gabrilovich DI. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J Immunol 1998;161:4842-51.
12. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cellsi n gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573-7.
13. Lissoni P. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeostatic Agents 2001;15:140-4.
14. Almand B. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
15. Takahashi A. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004;53:543-50.
16. Fan XH, Han BH, Dong QG, Sha HF, Bao GL, Liao ML. [Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma]. Zhonghua Jie He He Hu Xi Za Zhi 2003;26:539-43.
17. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 1998;160:1224.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299-307.
20. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
21. Almand B, Resser J, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
22. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.
23. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45.
24. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
25. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9.
26. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
27. + cells. J Immunol 1998;161:5313-20.
28. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
29. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260-8.
30. Gabrilovich DI, Ishida T, Nadaf S, Ohm J, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70.
31. Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeostatic Agents 2001;15:140.
32. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004;53:543-50.
33. Kikuchi K, Kus ama K, Sano M, et al. Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity. Anticancer Res 2006;26:1833-48.
34. Della Porta M, Danova M, Rigolin GM, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005;68:276-84.
35. Tsukayama S, Omura K, Yoshida K, Tanaka Y, Watanabe G. Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer. Oncol Rep 2005;14:369-75.
36. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci US A 2002;99:11393-8.
37. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
38. Freedman RS, Vadhan-Raj S, Butts C, etal. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003;9:5228-37.